Drugs / ZT003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07184502 | Oct 2025 → Jun 2026 overdue | — | Beijing QL Biopharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07184502 ↗ |
| Route | Subcutaneous | “ZT003 is administered as a single subcutaneous injection at different dose levels.” NCT07184502 ↗ |